Orlando, FL -- (SBWIRE) -- 10/10/2013 -- Hot Stock Profits provides investors and traders with valuable trading tools and content as well as micro-cap stock alerts via eMail and text messages. To Join Our Text Message Alerts Service Just Text The Word Stocks To 555888 From Your Cell Phone. Our Focus Today Is On Inovio Pharmaceuticals Inc (NYSEMKT:INO), Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX).
Inovio Pharmaceuticals Inc (NYSEMKT:INO) shares gained 0.47% to $2.13. The company announced that Dr. J. Joseph Kim, President and CEO, was invited to participate in a panel discussion at the 12(th) Annual BIO Investor Forum on October 8-9, 2013 at Palace Hotel, San Francisco, CA.
Additionally, the company on Sept. 24 announced the publication of a peer-reviewed paper demonstrating the success of its new DNA plasmid technology in generating therapeutic monoclonal antibodies. In this study in mice, a prototype monoclonal antibody construct encoding for an established anti-HIV monoclonal antibody (VRC01) was created as a DNA plasmid using Inovio's patented DNA optimization technology, including codon/RNA optimization and leader sequence utilization, and delivered with its CELLECTRA® adaptive electroporation device.
Are investors worried about the recent updates with INO? Find out with a free trend analysis HERE
Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) shares declined 8.52% to $3.65. The company on Oct. 1 announced a poster presentation featuring preclinical data for its uridine nucleotide prodrug candidate for the treatment of hepatitis C virus (HCV) infection at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which will take place in Washington, DC, November 1-5, 2013. Full abstracts can now be viewed at the AASLD website at www.aasld.org.
The following abstract will be presented in a poster session during the AASLD Annual Meeting in the Poster Hall on Saturday, November 2, 2013, 2:00pm – 7:30pm Eastern Time: Abstract No. 485: "A Novel Uridine Nucleotide Prodrug, IDX20963, and Its Potential for Use in a Low-Dose Direct-Acting Antiviral Regimen for HCV."
Is IDIX going to continue its rally or drop like a rock? Find out with a free trend analysis HERE
Join Our Mobile SMS Alerts By Texting Stocks To 555888
HotStockProfits.com continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.
HotStockProfits.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit HotStockProfits.com website, for complete risks and disclosures.
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)